Rodman & Renshaw Downgrades Pharmacopeia (PCOP) to Market Perform
More News related to PCOP
- Pharmacopeia to Request a Hearing With NASDAQ Following Receipt of Notice of Non-Compliance
- Pharmacopeia (PCOP) Tops Q3 View By 20c
- Ligand Pharmaceuticals Announces Third Quarter Results
- Pharmacopeia Announces Third Quarter 2008 Financial Results
- Trading Radar for 11/06: Disney (DIS), Anheuser-Busch (BUD), NVIDIA (NVDA), Nasdaq (NDAQ), Toyota (TM), Priceline.com (PCLN) Reports; Initial Jobless Claims, Preliminary Productivity for Q3 Due
More News related to Downgrades
- Merrill Smacks Down the REIT Space: Downgrades 29 Stocks, Upgrades 2
- Solars Rise as Merrill Downgrades First Solar (FSLR), SunPower (SPWRA)
- Merrill Lynch Downgrades Autodesk (ADSK) to Underperform
- Friedman Billings Downgrades Goodrich (GR) to Market Perform
- Friedman Billings Downgrades Spirit AeroSystems (SPR) to Market Perform
Rodman & Renshaw downgrades Pharmacopeia (Nasdaq: PCOP) from Market Outperform to Market Perform.
Rodman analyst says, "On Wednesday September 24th, Ligand Pharmaceuticals (LGND) agreed to acquire Pharmacopeia agreed to acquire Pharmacopeia for consideration of $55MM. Also, Contingent Value Rights (CVRs), currently valued at an additional $15MM, will be paid to PCOP shareholders in the event that LGND agrees to partner lead compound PS433540 (DARA) by 2011."
Pharmacopeia, Inc. is a clinical development stage biopharmaceutical company dedicated to discovering and developing small molecule therapeutics to address medical needs.
Related Categories
DowngradesStocks Mentioned
+0.12Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
